BPG is committed to discovery and dissemination of knowledge
Basic Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Oncol. Nov 24, 2026; 17(11): 124935
Published online Nov 24, 2026. doi: 10.5306/wjco.124935
HN1 L promotes colorectal cancer proliferation and migration by inhibiting the Hippo pathway
Da Kang, Ling-Xin Zeng, Rong-Xin Zhang, Wen-Juan Ma, Rong Yang, Xin Wang
Da Kang, Rong-Xin Zhang, Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Da Kang, Rong-Xin Zhang, Wen-Juan Ma, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Ling-Xin Zeng, Xin Wang, Department of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, Qingyuan 511518, Guangdong Province, China
Wen-Juan Ma, Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Rong Yang, Department of Intensive Care Unit, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong Province, China
Co-first authors: Da Kang and Ling-Xin Zeng.
Author contributions: Kang D, Zeng LX contributed to methodology, formal analysis, investigation, data curation, writing-original draft, writing-review and editing, visualization, both authors have made crucial and indispensable contributions towards the completion of the project and thus qualified as the co-first authors of the paper; Zhang RX, Ma WJ contributed to methodology, data curation, visualization; Wang X, Yang R contributed to conceptualization, validation, resources, writing-review and editing, project administration, funding acquisition.
AI contribution statement: Portions of this manuscript were edited using AI tools solely for language refinement, formatting assistance, and improvement of clarity. The authors carefully reviewed, verified, and approved all AI-assisted outputs and take full responsibility for the scientific content of the manuscript. AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Supported by 2020 Annual Open Research Fund of the Sixth Affiliated Hospital of Guangzhou Medical University, No. 202011-103 and No. 202301-314; 2022 Special Fund of Qingyuan People’s Hospital, No. QYRYCRC2023015.
Institutional review board statement: This study was carried out according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committees of Sun Yat-Sen University Cancer Center (No. G2022-209-01).
Institutional animal care and use committee statement: All animal experiments were reviewed and approved by the Animal Ethics Committee of Sun Yat-sen University Cancer Center (No. L102042020120B). All procedures involving animals were performed in accordance with institutional guidelines for animal care and use.
Conflict-of-interest statement: The authors declare that they have no competing interests.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The public datasets analyzed in this study are available from The Cancer Genome Atlas and Gene Expression Omnibus database. Additional data generated or analyzed during the current study are available from the corresponding author upon reasonable request.
Corresponding author: Xin Wang, MD, Professor, Department of Oncology, The Affiliated Qingyuan Hospital (Qingyuan People’s Hospital), Guangzhou Medical University, No. 35 Yinquan North Road, Qingcheng District, Qingyuan 511518, Guangdong Province, China. xinwang@gzhmu.edu.cn
Received: June 30, 2026
Revised: August 14, 2026
Accepted: October 22, 2026
Published online: November 24, 2026
Processing time: 142 Days and 16.9 Hours
Abstract
BACKGROUND

Postoperative recurrence and metastasis significantly hinder long-term survival in colorectal cancer (CRC), with varied responses to adjuvant chemotherapy observed among patients possessing similar clinical characteristics. HN1 L has been implicated in the progression of several malignancies; however, its biological function, regulatory mechanism, and clinical relevance in CRC remain inadequately defined.

AIM

To characterize the expression pattern and oncogenic function of HN1 L in CRC, investigate its association with Hippo signaling, and explore its association with postoperative risk stratification and adjuvant chemotherapy selection.

METHODS

HN1 L expression and clinical relevance were assessed using transcriptomic and clinical data from The Cancer Genome Atlas, single-cell RNA sequencing data from GSE132465, immunohistochemical (IHC) analyses of 84 paraffin-embedded CRC specimens, and an independent cohort comprising 10 paired frozen CRC and adjacent normal tissues for Western blot (WB). Stable HN1 L-overexpressing and knockdown CRC cell lines underwent quantitative real-time polymerase chain reaction, WB, RNA sequencing, pathway enrichment analysis, as well as proliferation and migration assays. In vivo tumor-promoting effects of HN1 L were evaluated using xenograft models and IHC. Kaplan-Meier analysis, time-dependent receiver operating characteristic curves, Cox regression, and HN1 L expression-by-chemotherapy interaction analysis were utilized to examine clinical associations.

RESULTS

HN1 L exhibited upregulation in CRC, predominantly within tumor epithelial cells. Its overexpression augmented proliferation and migration, while knockdown induced the opposite effects. Endpoint xenograft outcomes and Ki-67 staining further corroborated its tumor-promoting role in vivo. Mechanistically, HN1 L diminished MOB1 and YAP phosphorylation, particularly at YAP Ser127 and Ser397, while elevating SNAIL expression, with overall YAP levels remaining largely unchanged. In the clinical cohort, baseline characteristics were generally consistent between HN1 L-high and HN1 L-low groups. High HN1 L expression correlated with reduced five-year overall survival (60% 95%CI: 34%-100% vs 96% 95%CI: 87%-100%, log-rank P = 0.039). Among HN1 L-high patients, the five-year disease-free survival (DFS) was 92% with adjuvant chemotherapy compared to 52% without. A significant HN1 L-by-chemotherapy interaction was noted for DFS (interaction hazard ratio = 0.09, 95%CI: 0.008-0.901; P = 0.031).

CONCLUSION

HN1 L promotes CRC progression by suppressing Hippo pathway activity. Elevated HN1 L expression correlates with poorer clinical outcomes and differential adjuvant chemotherapy benefit in this retrospective cohort, thereby supporting its potential role in CRC risk stratification and treatment selection.

Keywords: Colorectal cancer; HN1 L; Hippo pathway; Adjuvant therapy; Prognosis

Core Tip: This study identifies HN1 L as an oncogenic regulator in colorectal cancer (CRC). Integrated transcriptomic, cellular, xenograft, and clinical analyses demonstrate that HN1 L enhances CRC proliferation and migration by inhibiting Hippo pathway activity, primarily through reduced MOB1 and YAP phosphorylation. Clinically, high HN1 L expression was associated with poorer five-year overall survival, while an exploratory interaction analysis suggested a possible difference in adjuvant chemotherapy benefit according to HN1 L expression. These findings suggest that HN1 L may function as a chemotherapy-response indicator and a potential therapeutic target in CRC.

Write to the Help Desk